Brief: NGM Discloses Third Oncology Development Candidate, Ngm438

NGM Biopharmaceuticals

09/12/2020 21:16

Dec 9 (Reuters) - NGM Biopharmaceuticals Inc  NGM.O :
    * NGM DISCLOSES THIRD ONCOLOGY DEVELOPMENT CANDIDATE,
NGM438, A
NOVEL ANTAGONIST ANTIBODY INHIBITING LAIR1 FOR TREATMENT OF
ADVANCED SOLID TUMORS
    * NGM BIOPHARMACEUTICALS INC - PLANS TO INITIATE
FIRST-IN-HUMAN
TESTING OF NGM438 IN 4Q21
    * NGM BIOPHARMACEUTICALS INC - FIRST-IN-HUMAN TESTING FOR
NGM707
IS EXPECTED TO BEGIN IN MID-2021
    * NGM BIOPHARMACEUTICALS INC -  NGM438, NGM707 AND NGM120
WERE
DISCOVERED BY CO UNDER ITS STRATEGIC COLLABORATION WITH MERCK

Source text for Eikon:  ID:nGNX153RWT 
Further company coverage:  NGM.O 

 ((Reuters.Briefs@thomsonreuters.com;))